Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody

Molecular Pharmaceutics

Volumn 9, Issue 5, 2012, Pages 1441-1448

  Engle, Jonathan W ^a   Hong, Hao ^b   Zhang, Yin ^a   Valdovinos, Hector F ^a   Myklejord, Duane V ^b   Barnhart, Todd E ^a   Theuer, Charles P ^c   Nickles, Robert J ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TRACON Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

66Ga; breast cancer; CD105 endoglin; positron emission tomography (PET); TRC105; tumor angiogenesis

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ENDOGLIN; GALLIUM 66; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRC105; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION MEASUREMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GALLIUM RADIOISOTOPES; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY;

EID: 84860755290     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300019c     Document Type: Article

References (46)

1. 68Ga-based imaging agents: chemistry and diversity Med. Chem. 2011, 7, 345-379
2. Even-Sapir, E.; Israel, O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma Eur. J. Nucl. Med. Mol. Imaging 2003, 30 (Suppl 1) S65-S81
3. 66Ga Phys. Rev. C 2010, 82, 067301
4. Laforest, R.; Rowland, D. J.; Welch, M. J. MicroPET imaging with nonconventional isotopes IEEE Trans. Nucl. Sci. 2002, 49, 2119-2126
5. 66Ga an an isotope for PET imaging and quantification Med. Phys. 1997, 24, 317-327
6. Ugur, O.; Kothari, P. J.; Finn, R. D.; Zanzonico, P.; Ruan, S.; Guenther, I.; Maecke, H. R.; Larson, S. M. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors Nucl. Med. Biol. 2002, 29, 147-157
7. Lewis, M. R.; Reichert, D. E.; Laforest, R.; Margenau, W. H.; Shefer, R. E.; Klinkowstein, R. E.; Hughey, B. J.; Welch, M. J. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals Nucl. Med. Biol. 2002, 29, 701-706
8. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals Nucl. Med. Biol. 2003, 30, 725-731
9. 66Ga-DTPA-chitosan in fibrosarcoma bearing mice Nuckleonika 2011, 56, 41-47
10. 67Ga citrate from zinc and copper target materials by anion exchange Appl. Radiat. Isot. 2003, 59, 329-331
11. 66/68Ga from zinc targets for PET. Appl. Radiat. Isot. 2012, in press.
12. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
13. Fonsatti, E.; Altomonte, M.; Nicotra, M. R.; Natali, P. G.; Maio, M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels Oncogene 2003, 22, 6557-6563
14. Dallas, N. A.; Samuel, S.; Xia, L.; Fan, F.; Gray, M. J.; Lim, S. J.; Ellis, L. M. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy Clin. Cancer Res. 2008, 14, 1931-1937
15. Fonsatti, E.; Nicolay, H. J.; Altomonte, M.; Covre, A.; Maio, M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours Cardiovasc. Res. 2010, 86, 12-19
16. Seon, B. K.; Haba, A.; Matsuno, F.; Takahashi, N.; Tsujie, M.; She, X.; Harada, N.; Uneda, S.; Tsujie, T.; Toi, H.; Tsai, H.; Haruta, Y. Endoglin-targeted cancer therapy Curr. Drug Delivery 2011, 8, 135-43
17. Bredow, S.; Lewin, M.; Hofmann, B.; Marecos, E.; Weissleder, R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin Eur. J. Cancer 2000, 36, 675-681
18. Fonsatti, E.; Jekunen, A. P.; Kairemo, K. J.; Coral, S.; Snellman, M.; Nicotra, M. R.; Natali, P. G.; Altomonte, M.; Maio, M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model Clin. Cancer Res. 2000, 6, 2037-2043
19. Korpanty, G.; Carbon, J. G.; Grayburn, P. A.; Fleming, J. B.; Brekken, R. A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature Clin. Cancer Res. 2007, 13, 323-330
20. Hong, H.; Yang, Y.; Zhang, Y.; Engle, J. W.; Barnhart, T. E.; Nickles, R. J.; Leigh, B. R.; Cai, W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1335-1343
21. Zhang, Y.; Hong, H.; Cai, W. PET tracers based on Zirconium-89 Curr. Radiopharm. 2011, 4, 131-139
22. Yang, Y.; Zhang, Y.; Hong, H.; Liu, G.; Leigh, B. R.; Cai, W. In vivo near-infrared fluorescence imaging of CD105 expression Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 2066-2076
23. 89Zr-Df-TRC105 Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 138-148
24. Deshpande, N.; Ren, Y.; Foygel, K.; Rosenberg, J.; Willmann, J. K. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging Radiology 2011, 258, 804-811
25. Mendelson, D. S.; Gordon, M. S.; Rosen, L. S.; Hurwitz, H.; Wong, M. K.; Adams, B. J.; Alvarez, D.; Seon, B. K.; Theuer, C. P.; Leigh, B. R. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer J. Clin. Oncol. 2010, 28, 15s
26. Goldberg, R. M. Cetuximab Nat. Rev. Drug Discovery 2005, Suppl, S10-S11
27. 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA PLoS One 2011, 6, e28005
28. Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Barnhart, T. E.; Cai, W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab Am. J. Nucl. Med. Mol. Imaging 2012, 2, 1-13
29. Takahashi, N.; Haba, A.; Matsuno, F.; Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide Cancer Res. 2001, 61, 7846-7854
30. Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Theuer, C. P.; Barnhart, T. E.; Cai, W. Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody Mol. Pharm. 2012, 9, 645-653
31. Cai, W.; Chen, K.; Mohamedali, K. A.; Cao, Q.; Gambhir, S. S.; Rosenblum, M. G.; Chen, X. PET of vascular endothelial growth factor receptor expression J. Nucl. Med. 2006, 47, 2048-2056
32. 3 Cancer Res. 2006, 66, 9673-9681
33. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review J. Controlled Release 2000, 65, 271-284
34. Gambhir, S. S.; Czernin, J.; Schwimmer, J.; Silverman, D. H.; Coleman, R. E.; Phelps, M. E. A tabulated summary of the FDG PET literature J. Nucl. Med. 2001, 42, 1S-93S
35. 18F-FDG PET in sarcoma treatment response imaging Am. J. Nucl. Med. Mol. Imaging 2011, 1, 47-53
36. Vach, W.; Høilund-Carlsen, P. F.; Fischer, B. M.; Gerke, O.; Weber, W. How to study optimal timing of PET/CT for monitoring of cancer treatment Am. J. Nucl. Med. Mol. Imaging 2011, 1, 54-62
37. 11C-acetate Am. J. Nucl. Med. Mol. Imaging 2012, 2, 33-47
38. Disselhorst, J. A.; Brom, M.; Laverman, P.; Slump, C. H.; Boerman, O. C.; Oyen, W. J.; Gotthardt, M.; Visser, E. P. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner J. Nucl. Med. 2010, 51, 610-617
39. Ruggiero, A.; Holland, J. P.; Lewis, J. S.; Grimm, J. Cerenkov luminescence imaging of medical isotopes J. Nucl. Med. 2010, 51, 1123-1130
40. Thorek, D. L. J.; Robertson, R.; Bacchus, W. A.; Hahn, J.; Rothberg, J.; Beattie, B. J.; Grimm, J. Cerenkov imaging-a new modality for molecular imaging Am. J. Nucl. Med. Mol. Imaging 2012, 2, 163-173
41. 18F-based radiotracers Am. J. Nucl. Med. Mol. Imaging 2012, 2, 55-76
42. Hao, G.; Hajibeigi, A.; De León-Rodríguez, L. M.; Öz, O. K.; Sun, X. Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression Am. J. Nucl. Med. Mol. Imaging 2011, 1, 65-75
43. Wang, R. E.; Niu, Y.; Wu, H.; Amin, M. N.; Cai, J. Development of NGR peptide-based agents for tumor imaging Am. J. Nucl. Med. Mol. Imaging 2011, 1, 36-46
44. Cai, W.; Ebrahimnejad, A.; Chen, K.; Cao, Q.; Li, Z. B.; Tice, D. A.; Chen, X. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 2024-2036
45. Roopenian, D. C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 2007, 7, 715-725
46. Jefferis, R.; Lefranc, M. P. Human immunoglobulin allotypes: possible implications for immunogenicity MAbs 2009, 1, 332-338